Jose Carlo M. Artiaga

Jose Carlo M. Artiaga

Auto-generated profile, based on publicly available information

Jose Carlo M. Artiaga

Department of Ophthalmology and Visual Sciences, Philippine General Hospital, University of the Philippines Manila, Manila City, Philippines

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in Eye
Verified
Journal Article
Closed access
PDF file
JAJose Carlo M. Artiaga
Jose Carlo M. Artiaga
MGMa. Carmela B. Guevarra
Ma. Carmela B. Guevarra
GSGeorge Michael N. Sosuan
George Michael N. Sosuan
AAAkshay Prashant Agnihotri
Akshay Prashant Agnihotri
INInes Doris Nagel
Ines Doris Nagel
FKFritz Kalaw
Fritz Kalaw

1 March 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
CACorrina P Azarcon
Corrina P Azarcon
JAJose Carlo M Artiaga
Jose Carlo M Artiaga
NANavilas
Navilas
Purpose: To summarize key findings from a systematic review focusing on pain as an adverse outcome of panretinal photocoagulation (PRP) among patients with diabetic retinopathy. Design: Systematic review. Methods: We systematically searched articles in major databases from July to September 2020. Studies that compared pain outcomes of PRP among diabetic patients who underwent conventional single-spot laser (SSL), conventional multi-spot laser (MSL), and/or novel navigated laser (NNL) were included. The Cochrane RoB 2 tool and ROBINS-I tool were used to evaluate the risk of bias of the included randomized controlled trials (RCTs) and controlled clinical trials (CCTs), respectively. Results: We included 13 RCTs and 4 CCTs. Thirteen studies were included for Comparison 1 (Conventional SSL versus Conventional MSL), 3 studies were included for Comparison 2 (NNL versus Conventional MSL), and 3 studies were included for Comparison 3 (NNL versus Conventional SSL). A total of 783 patients and 1961 eyes were included in this review. The review showed that NNL yielded the lowest pain scores, followed by conventional MSL, then by conventional SSL. Conclusion: This review summarizes findings of multiple studies that reported pain as an adverse outcome of PRP among patients with advanced diabetic retinopathy. Data from RCTs with mostly some concerns for bias (RoB 2 tool) and CCTs with mostly moderate risk of bias (ROBINS-I tool) show benefit of using MSL over SSL, and NNL over conventional systems for PRP in diabetic retinopathy, considering pain as the primary outcome.

2 October 2024 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
JAJose Carlo M. Artiaga
Jose Carlo M. Artiaga
SWShiao Wei Wong
Shiao Wei Wong
DMDeepthy Menon
Deepthy Menon
SKSwetha Kumar
Swetha Kumar
PDPankaja Dhoble
Pankaja Dhoble
LNLuke Nicholson
Luke Nicholson

1 June 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
HUHarvey S Uy
Harvey S Uy
JAJose Carlo M Artiaga
Jose Carlo M Artiaga
Objective: To compare the effectiveness, procedure time and safety outcomes of two different intravitreal injections (IVI) techniques. Methods: This was a prospective, single-center, randomized clinical trial of 200 adult eyes receiving intravitreal medications for various indications. Eyes were assigned (1:1) to undergo IVI using either an intravitreal injection guide (IIG) (n= 100) or conventional dual blade speculum plus surgical caliper (DBS) (n=100). All IVI were administered using a 30-gauge needle placed 4 mm posterior to the inferior limbus. The main outcome measures were rate of successful IVI administration, procedure time (seconds) as measured by a stopwatch from application to removal of IIG or DBS, patient preference for IVI technique and adverse events. Results: The two groups were similar in terms of mean age (P=0.398), laterality (P=0.671), indication for treatment (P=0.175) and medication type (P=0.489). All IVI procedures were successfully completed in both groups. The mean procedure time was shorter using the IIG (9.94 ± 2.87 seconds) versus DBS (21.85 ± 7.25 seconds) technique (P ≤ 0.01). The incidence of post-injection subconjunctival hemorrhage was higher when the DBS was applied (OR = 2.35, 95% CI = 1.22– 4.53). Patients with previous history of IVI preferred the IIG over the DBS. No other injection-related adverse events were observed in both groups. Conclusion: DBS and IIG techniques are similarly effective and safe for the administration of intravitreal medications. The IIG appears to significantly reduce procedure time, be associated with a lower incidence of subconjunctival hemorrhage and engender better patient acceptance. Clinical Trial Registration: ClinicalTrials.gov (NCT04455399).

8 January 2024 in Eye
Verified
Journal Article
Closed access
PDF file
JAJose Carlo M. Artiaga
Jose Carlo M. Artiaga
CACorrina P. Azarcon
Corrina P. Azarcon
FLFaye D. Levina
Faye D. Levina
ABAlbert John Bromeo
Albert John Bromeo
BMBryan Vincent Q. Mesina
Bryan Vincent Q. Mesina
CACheryl A. Arcinue
Cheryl A. Arcinue

28 November 2023 in Eye
Verified
Journal Article
Closed access
PDF file
KCKarl Gerard R. Crisostomo
Karl Gerard R. Crisostomo
JDJustine Karl Patrick C. Dantes
Justine Karl Patrick C. Dantes
DMDavid Marco M. Magpantay
David Marco M. Magpantay
JAJose Carlo M. Artiaga
Jose Carlo M. Artiaga